BTG Plc operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BTG Plc with three other
pharmaceutical manufacturers in Europe:
Dechra Pharmaceuticals PLC
sales of £359.28 million [US$473.98 million]
of which 63%
was European Pharmaceuticals),
(£217.10 million [US$286.41 million]
of which 100%
was Antibodies & Related Products), and
Dottikon ES Holding AG
based in Switzerland
(151.75 million Swiss Francs [US$155.16 million]
of which 89%
was Pharma Products).
BTG Plc reported sales of £570.50 million (US$752.64 million)
March of 2017.
increase of 27.5%
versus 2016, when the company's sales were £447.50 million.
Sales at BTG Plc have increased during each of the previous five years
(and since 2012, sales have increased a total of 190%).
Sales of Interventional Medicine saw an increase
43.9% in 2017, from
£150.20 million to £216.20 million.